{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:10:18Z","timestamp":1780629018165,"version":"3.54.1"},"reference-count":20,"publisher":"Japan Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1507\/endocrj.ej12-0417","type":"journal-article","created":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T22:42:02Z","timestamp":1358548922000},"page":"651-663","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism"],"prefix":"10.1507","volume":"60","author":[{"given":"Akira","family":"Shimatsu","sequence":"first","affiliation":[{"name":"Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nippon Medical School, Tokyo 113-8603, Japan"},{"name":"Tokyo Rosai Hospital, Tokyo 143-0013, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Hizuka","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Tokyo Women\u2019s Medical University, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kitai","sequence":"additional","affiliation":[{"name":"Teijin Pharma Limited, Tokyo 100-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Ramis","sequence":"additional","affiliation":[{"name":"Ipsen Innovation, Les Ulis 91940, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Chihara","sequence":"additional","affiliation":[{"name":"Hyogo Prefectural Kakogawa Medical Center, Kakogawa 675-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Melmed S (2006) Medical progress: acromegaly<i>. N Engl J Med<\/i> 355: 2558-2573.","DOI":"10.1056\/NEJMra062453"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. <i>Endocr Rev<\/i> 25: 102-152.","DOI":"10.1210\/er.2002-0022"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Alexander L, Applenton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. <i>Clin Endocrinol<\/i> <i>(Oxf)<\/i> 12: 71-79.","DOI":"10.1111\/j.1365-2265.1980.tb03135.x"},{"key":"4","unstructured":"4. Bates AS, Van&rsquo;t Hoff W, Jones JM, Clayton RN (1993) An audit of outcome of treatment in acromegaly. <i>Q J Med<\/i> 86: 293-299."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. <i>Pituitary<\/i> 2: 29-41.","DOI":"10.1023\/A:1009965803750"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. <i>Clin Endocrinol<\/i> <i>(Oxf)<\/i> 41: 95-102.","DOI":"10.1111\/j.1365-2265.1994.tb03789.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Melmed S, Colao A, Barkan M, Molitch A, Grossman AB, et al. (2009) Guidelines for acromegaly management: an update. <i>J Clin Endocrinol Metab <\/i>94: 1509-1517.","DOI":"10.1210\/jc.2008-2421"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ciccarelli A, Daly A, Beckers A (2004) Lanreotide Autogel<sup>&reg;<\/sup> for acromegaly: A new addition to the treatment armamentarium. <i>Treat Endocrinol<\/i> 3: 77-81.","DOI":"10.2165\/00024677-200403020-00002"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Melmed S, Cook D, Schopohl J, Goth MI, Lam KSL, et al. (2010) Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel<sup>&reg;<\/sup> therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. <i>Pituitary<\/i> 13: 18-28.","DOI":"10.1007\/s11102-009-0191-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, et al. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. <i>J Clin Endocrinol Metab<\/i> 87: 99-104.","DOI":"10.1210\/jcem.87.1.8153"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Alfonso AMP, et al. (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. <i>Clin Endocrinol<\/i> <i>(Oxf)<\/i> 60: 734-740.","DOI":"10.1111\/j.1365-2265.2004.02045.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. <i>Clin Endocrinol (Oxf)<\/i> 64: 209-214.","DOI":"10.1111\/j.1365-2265.2006.02450.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, et al. (2008) Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. <i>Clin Endocrinol<\/i> <i>(Oxf)<\/i> 69: 299-305.","DOI":"10.1111\/j.1365-2265.2008.03208.x"},{"key":"14","unstructured":"14. Croxtall JD, Scott LJ (2008) Lanreotide Autogel<sup>&reg;<\/sup>: A review of its use in the management of acromegaly. <i>Drugs<\/i> 68: 711-723."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. <i>J Clin Endocrinol Metab<\/i> 93: 2957-2968.","DOI":"10.1210\/jc.2008-0027"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, et al. (2012) Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. <i>Pituitary<\/i> 15: 398-404.","DOI":"10.1007\/s11102-011-0335-y"},{"key":"17","unstructured":"17. Research Study Group on the Hypothalamo-Pituitary Dysfunction, the Ministry of Health, Labor and Welfare, Japan. Guidelines for the diagnosis and treatment of acromegaly and pituitary gigantism. Available at: http:\/\/rhhd.info\/pdf\/001001.pdf Accessed Dec 25, 2012 (In Japanese)."},{"key":"18","unstructured":"18. Shimatsu A, Fujieda K, Hanew K, Tanaka T, Yokoya S, et al. (1996) Clinical evaluation of serum IGF-I, IGF-II and IGFBP-3 measured by IRMA kits in adulthood. <i>Horumon to Rinsho<\/i> 44: 1129-1138 (In Japanese)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Oki Y, Inoue T, Imura M, Tanaka T, Genma R, et al. (2009) Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study. <i>Endocr J<\/i> 56: 1095-1101.","DOI":"10.1507\/endocrj.K09E-172"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Mazziotti G, Giustina A (2010) Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. <i>Pituitary<\/i> 13: 60-67.","DOI":"10.1007\/s11102-009-0169-z"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/5\/60_EJ12-0417\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:38:27Z","timestamp":1618295907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/5\/60_EJ12-0417\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej12-0417","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}